Diagnosis and Management of Anaplastic Thyroid Cancer

• Autores: Ashish V. Chintakuntlawar, R.L. Foote, Jan L. Kasperbauer, Keith C. Bible
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 48, Nº. 1, 2019, págs. 269-284
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Anaplastic thyroid cancer (ATC) is a devastating and usually incurable diagnosis. Clinical and pathologic diagnosis is best assessed at a tertiary center with concentrated ATC expertise. Expeditious multidisciplinary management is recommended for optimal patient outcomes. Based on multiinstitutional and population-based studies, multimodal therapy that includes chemoradiotherapy with surgery (when feasible) is the preferred initial treatment because it is associated with incrementally improved overall survival. In ATC that carries a BRAF V600E somatic mutation, combination therapy with BRAF and MEK inhibitors has shown promise but needs further study. Immunotherapeutic agents in neoadjuvant and metastatic settings are being investigated.